← Back to all trials
Active Not Recruiting
NCT07187375
Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
Conditions: Congenital Adrenal Hyperplasia
Sex: All
Ages: 0 Years – 23 Months
Healthy volunteers: No
Phase: PHASE2
Enrollment: 7
Sponsor: Neurocrine Biosciences
Location: Neurocrine Clinical Site Berlin
Summary
The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \
Eligibility Criteria
Key Inclusion Criteria:
* Be a female or male between 0 to \
Source: ClinicalTrials.gov (NCT07187375). StuddyBuddy aggregates publicly available trial information.
